13 results about "Cotinine" patented technology

The application provides a method for detecting psychotropic drugs in environmental sludge based on acid pretreatment, which comprises the following steps: S1: obtaining a sludge sample to be detected, performing pressurized fluid extraction on the sludge sample to be detected after freeze-drying to obtain an extraction solution, performing solid-phase extraction on the extraction solution to obtain an eluate, and redissolving the eluate to obtain a solution to be detected, wherein the pressurized fluid extraction is performed under the condition of 5 ‰ formic acid water without heating; and S2: performing liquid chromatography mass spectrometry on the solution to be detected to obtain a mass spectrum, wherein the psychotropic drug is one of eptazocine, codeine, AMP, MAMP, MDA, monoacetylmorphine, MDMA, PMMA, fentanyl, norfentanyl, ketamine, norfentanyl, benzoyl eptazocine, cocaine and tramadol, and the method realizes detection of multiple psychotropic drugs in environmental sludge.

This invention discloses a method for preparing a nano-zinc sulfide composite material, comprising: (1) dissolving ammonium molybdate in deionized water, stirring evenly to form a 50 g / L solution, then sequentially adding zinc acetate and thiourea, wherein the mass ratio of ammonium molybdate to zinc acetate and thiourea is 2:1, and stirring thoroughly to obtain a mixed solution; (2) transferring the obtained mixed solution to a reaction vessel, reacting at a constant temperature of 160℃ for 12 h, and obtaining a solid powder after treatment; (3) heat-treating at 300-400℃ for 2 h to obtain the nano-zinc sulfide composite material. This invention synthesizes zinc sulfide nanomaterials with different sizes and morphologies, while molybdenum dioxide nanoparticles modify the surface of zinc sulfide. The two work synergistically to have heterogeneous structural characteristics that promote and accelerate electron transport. Using them as electrode materials for electrochemical detection of nicotine and the metabolite cotinine content in cigarettes shows potential application advantages.

Disclosed herein are an anti-HER2 affibody and a switch molecule including a cotinine-conjugated anti-HER2 affibody. When applied in combination with Cot-sCART, the cotinine-conjugated anti-HER2 affibody reacts with HER2-positive cells to induce immune cell activity, thereby finding advantageous applications as switch molecules in sCART therapeutic agents.

The invention provides sporidiobolus roseus, application of the sporidiobolus roseus in tobacco leaf fermentation and a biological preparation. The sporidiobolus roseus is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 16, 2025, the address is No.3, yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.34236. The sporidiobolus roseus is named as sporidiobolus roseus, and the sporidiobolus roseus is named as sporidiobolus roseus. The strain can significantly increase the content of carotenoid degradation products, Maillard reaction products, chlorophyll degradation products, terpenoids and the like of tobacco leaves; the aroma amount, the aroma richness and the maturity of the cigar tobacco leaves are improved, and the aroma characteristic of the costustoot is highlighted; meanwhile, the sweetness of the tobacco product can be improved, and the caramel sweet and honey sweet note characteristics are highlighted; and the contents of nicotine, dehydroneonicotine and cotinine can be respectively reduced, so that the irritation and cleanliness of tobacco products are improved.

The invention provides heterobifunctional cotinine-containing compounds, pharmaceutical compositions, and methods of using same to treat medical conditions, such as pain.

The invention relates to the technical field of photoelectrochemical sensing, in particular to a novel PEC sensor based on a type II heterostructure and a preparation method and application thereof.The preparation method comprises the steps that WO3 and Mn-CdS are synthesized, the WO3 is dispersed and then reacts with a solution containing Mn (CH3COO) 3. 4H2O, Cd (CH3COO) 2. 2H2O and C2H5NS, and a WO3 / Mn-CdS (Wamp, MC) type II heterojunction composite material is prepared; the FTO is cleaned and dried by acetone, absolute ethyl alcohol and deionized water, and then is coated with Wamp; the MC dispersion liquid is solidified to obtain an electrode, antibodies Ab and BSA capable of specifically recognizing cotinine are modified to prepare a working electrode, the working electrode, a platinum wire auxiliary electrode and an Ag / AgCl reference electrode form a three-electrode system, and the electrode can be used for detecting cotinine in urine and saliva, meets the batch detection requirements of clinical tobacco exposure evaluation and the like, and has a wide application prospect.

The invention provides a synthetic method of levocotinine, and relates to the technical field of compound synthesis. According to the method, racemic nicotine is taken as a raw material, a resolving agent dissolved in an organic solvent is added, a system is adjusted to be alkaline after two times of reflux, and L-nicotine is obtained through extraction and vacuum concentration. And dissolving the obtained L-nicotine in a reaction solvent, adding sodium bicarbonate, uniformly mixing, reacting by taking iodine as an oxidizing agent, quenching the system after the reaction is finished, and extracting and concentrating under reduced pressure to obtain the target product L-cotinine. The method provided by the invention has the advantages of cheap and easily available raw materials, simple reaction steps, safe and simple operation, mild reaction conditions and environmental friendliness, has good repeatability and industrialization potential, is suitable for large-scale industrial production, and has remarkable economic and social benefits.

The invention provides heterobifunctional cotinine-containing compounds, pharmaceutical compositions, and methods of using same to treat medical conditions, such as a mast cell disease or pain.

The invention provides a pharmaceutical composition and application thereof, and relates to the technical field of medicine preparation. The pharmaceutical composition comprises S-(-)-cotinine or a pharmaceutically acceptable salt of the S-(-)-cotinine, and rivastigmine or a pharmaceutically acceptable salt of the rivastigmine. Compared with a single drug, the pharmaceutical composition containing S-(-)-cotinine and rivastigmine provided by the invention shows remarkable synergistic interaction and multi-target comprehensive intervention advantages, provides a new choice with better curative effect and more comprehensive action mechanism for treating neurodegenerative diseases such as Alzheimer's disease, and has a good application prospect.

The invention provides heterotrifunctional cotinine-containing compounds that are capable of binding both voltage-gated sodium channels NaV1.7 and NaV1.8, pharmaceutical compositions, and methods of using same to treat medical conditions, such as pain.

The use of pectins and / or polymers to prevent nicotine oxidation in tobacco containing products is disclosed. These polymers may be naturally occurring anionic polymers or synthetic polymers. These pectins and / or polymers prevent nicotine from oxidizing into cotinine, nicotine-cis-N-oxide, nicotine-trans-N-oxide, and / or nicotine-1,1-di-N-oxide. Molluscicides, algaecides, pesticides, and stabilized nicotine compositions comprising nicotine and pectin, anionic polymers, or combinations thereof are disclosed.

The present invention relates to an antibody or antigen-binding fragment thereof that targets cotinine, a chimeric antigen receptor comprising same, and uses thereof. The antibody of the present invention is an antibody that specifically binds to cotinine, and in particular, an antibody that binds more specifically to the S-isomer of cotinine than to the R-isomer thereof. In addition, the antibody has very low homology and a unique sequence, compared to the CDR sequences of conventional cotinine target antibodies. Cells expressing a chimeric antigen receptor comprising the anti-cotinine antibody or antigen-binding fragment of the present invention bind to a cotinine-conjugated switch and respond to a target cell line, thereby inducing immune cell activity. Therefore, the antibody or antigen-binding fragment thereof of the present invention can be used to suppress immune side effects due to overactivation of T cells through cotinine-mediated activation regulation of chimeric antigen receptor effector cells, and can be effectively used as a CAR-immune cell therapeutic agent.

The invention provides heterobifunctional cotinine-containing compounds, pharmaceutical compositions, and methods of using same to treat medical conditions, such as pain.